Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

BHADRESH PATEL

Allopathic & Osteopathic Physicians Internal Medicine

NPI
1003913252
CMS profile
226942
Location
BEVERLY HILLS, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2025 · Entire year

$749.06

42 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2025 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $749.06 42

By paying entity

PY2025 · entire year · sorted by reported total

Page 1 of 1; records 1–42 of 42 matching records. This page contains 42 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

BHADRESH PATEL

NPI 1003913252 · CMS profile ID 226942

Allopathic & Osteopathic Physicians / Internal Medicine

BEVERLY HILLS, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–42 of 42 matching records. This page contains 42 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1003913252?year=2025&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
BHADRESH PATEL, NPI 1003913252, CMS profile ID 226942. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–42 of 42 matching records. This page contains 42 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1003913252?year=2025&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
APA 7
IndustryPayments. (2026). BHADRESH PATEL, NPI 1003913252, CMS profile ID 226942. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–42 of 42 matching records. This page contains 42 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1003913252?year=2025&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
Bluebook
BHADRESH PATEL, NPI 1003913252, CMS profile ID 226942, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–42 of 42 matching records. This page contains 42 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1003913252?year=2025&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30

42 matching records · $749.06 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 42 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–42 of 42.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
AstraZeneca Pharmaceuticals LP $24.0011/25/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1206239993 CMS
Amgen Inc. $16.0511/11/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1228355339 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $26.3311/06/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1222864600 CMS
Amgen Inc. $18.4810/31/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1228355334 CMS
Amgen Inc. $14.8410/30/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1227045309 CMS
GlaxoSmithKline, LLC. $22.0810/30/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1191039363 CMS
Boston Scientific Corporation $30.4110/29/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1181149196 CMS
Amgen Inc. $14.7310/24/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1227045305 CMS
Novo Nordisk Inc $14.0310/20/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1189103740 CMS
Amgen Inc. $5.9010/09/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1227045307 CMS
GlaxoSmithKline, LLC. $14.6709/18/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1191594377 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $27.8509/16/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1222864595 CMS
GlaxoSmithKline, LLC. $20.3808/28/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1190773883 CMS
Kowa Pharmaceuticals America, Inc. $17.0308/19/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1243110610 CMS
Amgen Inc. $17.2008/08/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1228355323 CMS
Novo Nordisk Inc $19.4408/07/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1188961391 CMS
ABBVIE INC. $17.6508/04/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1203496803 CMS
Abbott Laboratories $23.0807/29/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1240960479 CMS
GlaxoSmithKline, LLC. $15.0607/23/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1190334133 CMS
AstraZeneca Pharmaceuticals LP $15.5607/16/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1206837534 CMS
PFIZER INC. $16.2207/14/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1229490965 CMS
Abbott Laboratories $24.8305/22/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1240936879 CMS
Xeris Pharmaceuticals, Inc. $19.4305/20/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1250150952 CMS
Amgen Inc. $14.4705/15/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1227045313 CMS
Amgen Inc. $2.9005/09/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1227045303 CMS
Sumitomo Pharma America, Inc. $15.3205/08/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1176702633 CMS
PFIZER INC. $19.0305/02/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1229155212 CMS
AstraZeneca Pharmaceuticals LP $15.9504/30/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1206818660 CMS
GlaxoSmithKline, LLC. $14.5604/17/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1190399282 CMS
Merck Sharp & Dohme LLC $17.6804/15/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1238280943 CMS
Amgen Inc. $16.9004/10/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1228355330 CMS
AstraZeneca Pharmaceuticals LP $14.9603/25/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1207055186 CMS
AstraZeneca Pharmaceuticals LP $15.4203/13/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1206509354 CMS
Novo Nordisk Inc $24.4003/06/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1189101960 CMS
ABBVIE INC. $24.0103/05/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1203496798 CMS
GlaxoSmithKline, LLC. $17.8102/26/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1191507538 CMS
Amgen Inc. $14.4402/14/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1227045315 CMS
AstraZeneca Pharmaceuticals LP $15.9302/12/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1206734565 CMS
Amgen Inc. $2.3302/06/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1227045311 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $24.5802/06/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1222864590 CMS
Amgen Inc. $19.8201/28/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1228355327 CMS
ABBVIE INC. $23.3001/24/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1203496792 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $1,622.73 32
PY2020 $547.52 37
PY2021 $1,137.72 67
PY2022 $676.49 44
PY2023 $599.21 34
PY2024 $518.32 33
PY2025 $749.06 42

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $472,003.52 172
PY2024 Principal investigator $421,638.32 23
PY2023 Principal investigator $317,080.95 398
PY2022 Principal investigator $272,453.35 534
PY2020 Principal investigator $3,172.98 4
PY2019 Principal investigator $1,202.28 5

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

398 records in PY2023

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ModernaTX, Inc. $2,182.38 12/14/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1042337869
Principal investigator 1 ModernaTX, Inc. $674.33 12/14/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042337875
Principal investigator 1 ModernaTX, Inc. $674.33 12/14/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042337877
Principal investigator 1 ModernaTX, Inc. $674.33 12/14/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042337879
Principal investigator 1 ModernaTX, Inc. $674.33 12/14/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042337881
Principal investigator 1 ModernaTX, Inc. $674.33 12/14/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042337889
Principal investigator 1 ModernaTX, Inc. $2,182.38 12/14/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1042337891
Principal investigator 1 ModernaTX, Inc. $674.33 12/14/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042337895
Principal investigator 1 ModernaTX, Inc. $674.33 12/14/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042337897
Principal investigator 1 ModernaTX, Inc. $674.33 12/14/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042337899
Principal investigator 1 ModernaTX, Inc. $674.33 12/14/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042337901
Principal investigator 1 ModernaTX, Inc. $2,182.38 12/14/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1042337903
Principal investigator 1 ModernaTX, Inc. $2,182.38 12/14/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1042337905
Principal investigator 1 ModernaTX, Inc. $674.33 12/14/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042337909
Principal investigator 1 ModernaTX, Inc. $674.33 12/14/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042337913
Principal investigator 1 ModernaTX, Inc. $2,182.38 12/14/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1042337915
Principal investigator 1 ModernaTX, Inc. $674.33 12/14/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042337923
Principal investigator 1 ModernaTX, Inc. $674.33 12/14/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042337925
Principal investigator 1 ModernaTX, Inc. $674.33 12/14/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042337927
Principal investigator 1 ModernaTX, Inc. $674.33 12/14/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042337937
Principal investigator 1 ModernaTX, Inc. $674.33 12/14/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042337939
Principal investigator 1 ModernaTX, Inc. $674.33 12/14/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042337941
Principal investigator 1 ModernaTX, Inc. $674.33 12/14/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042337945
Principal investigator 1 ModernaTX, Inc. $674.33 12/14/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042337947
Principal investigator 1 ModernaTX, Inc. $2,182.38 12/14/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1042337949
Principal investigator 1 ModernaTX, Inc. $674.33 12/14/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042337955
Principal investigator 1 ModernaTX, Inc. $2,182.38 12/14/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1042337963
Principal investigator 1 ModernaTX, Inc. $1,002.37 11/28/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042337621
Principal investigator 1 ModernaTX, Inc. $674.33 11/28/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042337623
Principal investigator 1 ModernaTX, Inc. $674.33 11/28/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042337625
Principal investigator 1 ModernaTX, Inc. $674.33 11/28/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042337627
Principal investigator 1 ModernaTX, Inc. $674.33 11/28/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042337637
Principal investigator 1 ModernaTX, Inc. $674.33 11/28/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042337639
Principal investigator 1 ModernaTX, Inc. $674.33 11/28/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042337671
Principal investigator 1 ModernaTX, Inc. $674.33 11/28/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042337673
Principal investigator 1 ModernaTX, Inc. $674.33 11/28/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042337675
Principal investigator 1 ModernaTX, Inc. $674.33 11/28/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042337687
Principal investigator 1 ModernaTX, Inc. $674.33 11/28/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042337689
Principal investigator 1 ModernaTX, Inc. $674.33 11/28/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042337697
Principal investigator 1 ModernaTX, Inc. $674.33 11/28/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042337699
Principal investigator 1 ModernaTX, Inc. $674.33 11/28/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042337701
Principal investigator 1 ModernaTX, Inc. $674.33 11/28/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042337705
Principal investigator 1 ModernaTX, Inc. $674.33 11/28/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042337715
Principal investigator 1 ModernaTX, Inc. $674.33 11/28/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042337717
Principal investigator 1 ModernaTX, Inc. $674.33 11/28/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042337719
Principal investigator 1 ModernaTX, Inc. $674.33 11/28/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042337733
Principal investigator 1 ModernaTX, Inc. $674.33 11/28/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042337735
Principal investigator 1 ModernaTX, Inc. $1,589.95 11/28/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1042337755
Principal investigator 1 ModernaTX, Inc. $674.33 11/28/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042337757
Principal investigator 1 ModernaTX, Inc. $674.33 11/28/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042337759
Principal investigator 1 ModernaTX, Inc. $674.33 11/28/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042337761
Principal investigator 1 ModernaTX, Inc. $674.33 11/28/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042337783
Principal investigator 1 ModernaTX, Inc. $674.33 11/28/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042337785
Principal investigator 1 ModernaTX, Inc. $674.33 11/28/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042337787
Principal investigator 1 ModernaTX, Inc. $674.33 11/28/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042337801
Principal investigator 1 ModernaTX, Inc. $674.33 11/28/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042337803
Principal investigator 1 ModernaTX, Inc. $674.33 11/28/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042337821
Principal investigator 1 ModernaTX, Inc. $674.33 11/28/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042337823
Principal investigator 1 ModernaTX, Inc. $674.33 11/28/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042337833
Principal investigator 1 ModernaTX, Inc. $674.33 11/28/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042337835
Principal investigator 1 ModernaTX, Inc. $674.33 11/28/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042337837
Principal investigator 1 ModernaTX, Inc. $674.33 10/30/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042337441
Principal investigator 1 ModernaTX, Inc. $674.33 10/30/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042337455
Principal investigator 1 ModernaTX, Inc. $674.33 10/30/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042337467
Principal investigator 1 ModernaTX, Inc. $674.33 10/30/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042337477
Principal investigator 1 ModernaTX, Inc. $674.33 10/30/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042337479
Principal investigator 1 ModernaTX, Inc. $1,002.37 10/30/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042337531
Principal investigator 1 ModernaTX, Inc. $674.33 10/30/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042337533
Principal investigator 1 ModernaTX, Inc. $674.33 10/30/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042337611
Principal investigator 1 ModernaTX, Inc. $2,036.58 10/26/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1042337457
Principal investigator 1 ModernaTX, Inc. $2,036.58 10/26/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1042337471
Principal investigator 1 ModernaTX, Inc. $2,036.58 10/26/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1042337483
Principal investigator 1 ModernaTX, Inc. $2,833.62 10/26/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1042337485
Principal investigator 1 ModernaTX, Inc. $2,036.58 10/26/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1042337489
Principal investigator 1 ModernaTX, Inc. $2,036.58 10/26/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1042337513
Principal investigator 1 ModernaTX, Inc. $2,036.58 10/26/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1042337551
Principal investigator 1 ModernaTX, Inc. $2,036.58 10/26/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1042337553
Principal investigator 1 ModernaTX, Inc. $2,036.58 10/26/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1042337561
Principal investigator 1 ModernaTX, Inc. $2,036.58 10/26/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1042337563
Principal investigator 1 ModernaTX, Inc. $2,036.58 10/26/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1042337575
Principal investigator 1 ModernaTX, Inc. $2,036.58 10/26/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1042337599
Principal investigator 1 ModernaTX, Inc. $2,036.58 10/26/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1042337601
Principal investigator 1 ModernaTX, Inc. $2,036.58 10/05/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1042337433
Principal investigator 1 ModernaTX, Inc. $2,036.58 10/05/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1042337463
Principal investigator 1 ModernaTX, Inc. $2,036.58 10/05/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1042337559
Principal investigator 1 ModernaTX, Inc. $674.33 10/02/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042337459
Principal investigator 1 ModernaTX, Inc. $674.33 10/02/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042337465
Principal investigator 1 ModernaTX, Inc. $674.33 10/02/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042337491
Principal investigator 1 ModernaTX, Inc. $674.33 10/02/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042337495
Principal investigator 1 ModernaTX, Inc. $674.33 10/02/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042337497
Principal investigator 1 ModernaTX, Inc. $674.33 10/02/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042337521
Principal investigator 1 ModernaTX, Inc. $674.33 10/02/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042337523
Principal investigator 1 ModernaTX, Inc. $674.33 10/02/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042337569
Principal investigator 1 ModernaTX, Inc. $1,002.37 10/02/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042337583
Principal investigator 1 ModernaTX, Inc. $674.33 10/02/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042337585
Principal investigator 1 ModernaTX, Inc. $6,695.00 09/11/2023 Non-covered Recipient Entity
CLINICAL BIOSAFETY SERVICES
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042060477
Principal investigator 1 ModernaTX, Inc. $674.33 09/11/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042337217
Principal investigator 1 ModernaTX, Inc. $674.33 09/11/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042337219
Principal investigator 1 ModernaTX, Inc. $674.33 09/11/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042337221
Principal investigator 1 ModernaTX, Inc. $674.33 09/11/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042337227
Principal investigator 1 ModernaTX, Inc. $674.33 09/11/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042337229
Principal investigator 1 ModernaTX, Inc. $674.33 09/11/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042337231
Principal investigator 1 ModernaTX, Inc. $674.33 09/11/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042337239
Principal investigator 1 ModernaTX, Inc. $674.33 09/11/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042337241
Principal investigator 1 ModernaTX, Inc. $674.33 09/11/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042337257
Principal investigator 1 ModernaTX, Inc. $674.33 09/11/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042337259
Principal investigator 1 ModernaTX, Inc. $674.33 09/11/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042337265
Principal investigator 1 ModernaTX, Inc. $674.33 09/11/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042337267
Principal investigator 1 ModernaTX, Inc. $674.33 09/11/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042337269
Principal investigator 1 ModernaTX, Inc. $674.33 09/11/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042337281
Principal investigator 1 ModernaTX, Inc. $674.33 09/11/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042337283
Principal investigator 1 ModernaTX, Inc. $674.33 09/11/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042337285
Principal investigator 1 ModernaTX, Inc. $674.33 09/11/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042337299
Principal investigator 1 ModernaTX, Inc. $674.33 09/11/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042337311
Principal investigator 1 ModernaTX, Inc. $674.33 09/11/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042337323
Principal investigator 1 ModernaTX, Inc. $674.33 09/11/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042337325
Principal investigator 1 ModernaTX, Inc. $674.33 09/11/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042337335
Principal investigator 1 ModernaTX, Inc. $674.33 09/11/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042337337
Principal investigator 1 ModernaTX, Inc. $674.33 09/11/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042337347
Principal investigator 1 ModernaTX, Inc. $674.33 09/11/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042337349
Principal investigator 1 ModernaTX, Inc. $674.33 09/11/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042337351
Principal investigator 1 ModernaTX, Inc. $674.33 09/11/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042337353
Principal investigator 1 ModernaTX, Inc. $674.33 09/11/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042337357
Principal investigator 1 ModernaTX, Inc. $674.33 09/11/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042337359
Principal investigator 1 ModernaTX, Inc. $674.33 09/11/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042337369
Principal investigator 1 ModernaTX, Inc. $674.33 09/11/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042337371
Principal investigator 1 ModernaTX, Inc. $674.33 09/11/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042337373
Principal investigator 1 ModernaTX, Inc. $674.33 09/11/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042337375
Principal investigator 1 ModernaTX, Inc. $674.33 09/11/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042337377
Principal investigator 1 ModernaTX, Inc. $674.33 09/11/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042337407
Principal investigator 1 ModernaTX, Inc. $674.33 09/11/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042337409
Principal investigator 1 ModernaTX, Inc. $674.33 09/11/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042337411
Principal investigator 1 ModernaTX, Inc. $674.33 09/11/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042337413
Principal investigator 1 ModernaTX, Inc. $674.33 09/11/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042337415
Principal investigator 1 ModernaTX, Inc. $674.33 09/11/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042337417
Principal investigator 1 ModernaTX, Inc. $674.33 09/11/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042337419
Principal investigator 1 ModernaTX, Inc. $674.33 09/11/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042337421
Principal investigator 1 ModernaTX, Inc. $674.33 09/11/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042337423
Principal investigator 1 ModernaTX, Inc. $674.33 09/11/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042337425
Principal investigator 1 ModernaTX, Inc. $674.33 09/11/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042337427
Principal investigator 1 ModernaTX, Inc. $674.33 09/11/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042337429
Principal investigator 1 ModernaTX, Inc. $1,848.26 09/07/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1042337233
Principal investigator 1 ModernaTX, Inc. $1,848.26 09/07/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1042337243
Principal investigator 1 ModernaTX, Inc. $630.59 09/07/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1042337271
Principal investigator 1 ModernaTX, Inc. $1,848.26 09/07/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1042337301
Principal investigator 1 ModernaTX, Inc. $4,271.34 09/07/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1042337327
Principal investigator 1 ModernaTX, Inc. $1,848.26 09/07/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1042337329
Principal investigator 1 ModernaTX, Inc. $1,848.26 09/07/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1042337355
Principal investigator 1 ModernaTX, Inc. $1,848.26 09/07/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1042337379
Principal investigator 1 ModernaTX, Inc. $1,848.26 09/07/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1042337381
Principal investigator 1 ModernaTX, Inc. $1,848.26 09/07/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1042337393
Principal investigator 1 ModernaTX, Inc. $630.59 09/07/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1042337405
Principal investigator 1 ModernaTX, Inc. $1,999.99 08/04/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1042337209
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1042337085
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1042337087
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1042337089
Principal investigator 1 ModernaTX, Inc. $4,271.34 06/12/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1042337091
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1042337093
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1042337095
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1042337097
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1042337099
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1042337101
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1042337103
Principal investigator 1 ModernaTX, Inc. $4,271.34 06/12/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1042337105
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1042337107
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1042337109
Principal investigator 1 ModernaTX, Inc. $721.71 06/12/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1042337111
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1042337113
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1042337115
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1042337117
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1042337119
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1042337121
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1042337123
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1042337125
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1042337127
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1042337129
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1042337131
Principal investigator 1 ModernaTX, Inc. $4,271.34 06/12/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1042337133
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1042337135
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1042337137
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1042337139
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1042337141
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1042337143
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1042337145
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1042337147
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1042337149
Principal investigator 1 ModernaTX, Inc. $4,271.34 06/12/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1042337151
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1042337153
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1042337155
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1042337157
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1042337159
Principal investigator 1 ModernaTX, Inc. $4,271.34 06/12/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1042337161
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1042337163
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1042337165
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1042337167
Principal investigator 1 ModernaTX, Inc. $4,271.34 06/12/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1042337169
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1042337171
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1042337173
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1042337175
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1042337177
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1042337179
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1042337181
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1042337183
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1042337185
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1042337187
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1042337189
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1042337191
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1042337193
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1042337195
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1042337197
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1042337199
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1042337201
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1042337203
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1042337205
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1042337207
Principal investigator 1 ModernaTX, Inc. $1,250.00 06/07/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1042336997
Principal investigator 1 ModernaTX, Inc. $2,500.00 06/07/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1042336999
Principal investigator 1 ModernaTX, Inc. $1,000.00 06/07/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1042337001
Principal investigator 1 ModernaTX, Inc. $10,000.00 06/07/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1042337003
Principal investigator 1 ModernaTX, Inc. $500.00 06/07/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1042337005
Principal investigator 1 ModernaTX, Inc. $674.33 05/18/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042336611
Principal investigator 1 ModernaTX, Inc. $674.33 05/18/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042336613
Principal investigator 1 ModernaTX, Inc. $1,002.37 05/18/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042336617
Principal investigator 1 ModernaTX, Inc. $674.33 05/18/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042336619
Principal investigator 1 ModernaTX, Inc. $674.33 05/18/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042336625
Principal investigator 1 ModernaTX, Inc. $1,002.37 05/18/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042336631
Principal investigator 1 ModernaTX, Inc. $1,002.37 05/18/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042336633
Principal investigator 1 ModernaTX, Inc. $1,002.37 05/18/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042336635
Principal investigator 1 ModernaTX, Inc. $674.33 05/18/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042336641
Principal investigator 1 ModernaTX, Inc. $1,002.37 05/18/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042336643
Principal investigator 1 ModernaTX, Inc. $674.33 05/18/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042336645
Principal investigator 1 ModernaTX, Inc. $674.33 05/18/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042336647
Principal investigator 1 ModernaTX, Inc. $674.33 05/18/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042336649
Principal investigator 1 ModernaTX, Inc. $1,002.37 05/18/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042336669
Principal investigator 1 ModernaTX, Inc. $674.33 05/18/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042336683
Principal investigator 1 ModernaTX, Inc. $674.33 05/18/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042336685
Principal investigator 1 ModernaTX, Inc. $1,002.37 05/18/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042336699
Principal investigator 1 ModernaTX, Inc. $736.60 05/18/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042336705
Principal investigator 1 ModernaTX, Inc. $674.33 05/18/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042336707
Principal investigator 1 ModernaTX, Inc. $674.33 05/18/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042336727
Principal investigator 1 ModernaTX, Inc. $674.33 05/18/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042336729
Principal investigator 1 ModernaTX, Inc. $674.33 05/18/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042336731
Principal investigator 1 ModernaTX, Inc. $674.33 05/18/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042336745
Principal investigator 1 ModernaTX, Inc. $674.33 05/18/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042336757
Principal investigator 1 ModernaTX, Inc. $674.33 05/18/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042336783
Principal investigator 1 ModernaTX, Inc. $674.33 05/18/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042336785
Principal investigator 1 ModernaTX, Inc. $674.33 05/18/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042336787
Principal investigator 1 ModernaTX, Inc. $674.33 05/18/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042336803
Principal investigator 1 ModernaTX, Inc. $674.33 05/18/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042336805
Principal investigator 1 ModernaTX, Inc. $1,340.00 05/08/2023 Non-covered Recipient Entity
CLINICAL BIOSAFETY SERVICES
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042060195
Principal investigator 1 ModernaTX, Inc. $6,995.00 05/02/2023 Non-covered Recipient Entity
CLINICAL BIOSAFETY SERVICES
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1042060373
Principal investigator 1 ModernaTX, Inc. $674.33 04/27/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042336501
Principal investigator 1 ModernaTX, Inc. $674.33 04/27/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042336503
Principal investigator 1 ModernaTX, Inc. $674.33 04/27/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042336505
Principal investigator 1 ModernaTX, Inc. $674.33 04/27/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042336507
Principal investigator 1 ModernaTX, Inc. $674.33 04/27/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042336509
Principal investigator 1 ModernaTX, Inc. $674.33 04/27/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042336511
Principal investigator 1 ModernaTX, Inc. $674.33 04/27/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042336513
Principal investigator 1 ModernaTX, Inc. $674.33 04/27/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042336515
Principal investigator 1 ModernaTX, Inc. $674.33 04/27/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042336517
Principal investigator 1 ModernaTX, Inc. $674.33 04/27/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042336519
Principal investigator 1 ModernaTX, Inc. $674.33 04/27/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042336521
Principal investigator 1 ModernaTX, Inc. $674.33 04/27/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042336523
Principal investigator 1 ModernaTX, Inc. $674.33 04/27/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042336525
Principal investigator 1 ModernaTX, Inc. $674.33 04/27/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042336527
Principal investigator 1 ModernaTX, Inc. $674.33 04/27/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042336529
Principal investigator 1 ModernaTX, Inc. $674.33 04/27/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042336531
Principal investigator 1 ModernaTX, Inc. $674.33 04/27/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042336533
Principal investigator 1 ModernaTX, Inc. $674.33 04/27/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042336535
Principal investigator 1 ModernaTX, Inc. $674.33 04/27/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042336537
Principal investigator 1 ModernaTX, Inc. $674.33 04/27/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042336539
Principal investigator 1 ModernaTX, Inc. $674.33 04/27/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042336541
Principal investigator 1 ModernaTX, Inc. $674.33 04/27/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042336543
Principal investigator 1 ModernaTX, Inc. $674.33 04/27/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042336545
Principal investigator 1 ModernaTX, Inc. $674.33 04/27/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042336547
Principal investigator 1 ModernaTX, Inc. $166.50 03/29/2023 Non-covered Recipient Entity
ELITE RESEARCH NETWORK - NATURE COAST CLINICAL RESEARCH LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1042136351
Principal investigator 1 ModernaTX, Inc. $674.33 03/13/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042336359
Principal investigator 1 ModernaTX, Inc. $674.33 03/13/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042336369
Principal investigator 1 ModernaTX, Inc. $674.33 03/13/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042336371
Principal investigator 1 ModernaTX, Inc. $674.33 03/13/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042336379
Principal investigator 1 ModernaTX, Inc. $674.33 03/13/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042336381
Principal investigator 1 ModernaTX, Inc. $674.33 03/13/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042336383
Principal investigator 1 ModernaTX, Inc. $674.33 03/13/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042336389
Principal investigator 1 ModernaTX, Inc. $674.33 03/13/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042336391
Principal investigator 1 ModernaTX, Inc. $674.33 03/13/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042336401
Principal investigator 1 ModernaTX, Inc. $674.33 03/13/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042336407
Principal investigator 1 ModernaTX, Inc. $674.33 03/13/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042336409
Principal investigator 1 ModernaTX, Inc. $1,002.37 03/13/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042336411
Principal investigator 1 ModernaTX, Inc. $14.58 03/13/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042336413
Principal investigator 1 ModernaTX, Inc. $674.33 03/13/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042336415
Principal investigator 1 ModernaTX, Inc. $674.33 03/13/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042336419
Principal investigator 1 ModernaTX, Inc. $1,002.37 03/13/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042336421
Principal investigator 1 ModernaTX, Inc. $674.33 03/13/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042336427
Principal investigator 1 ModernaTX, Inc. $674.33 03/13/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042336429
Principal investigator 1 ModernaTX, Inc. $674.33 03/13/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042336431
Principal investigator 1 ModernaTX, Inc. $14.58 03/13/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042336441
Principal investigator 1 ModernaTX, Inc. $674.33 03/13/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042336443
Principal investigator 1 ModernaTX, Inc. $674.33 03/13/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042336455
Principal investigator 1 ModernaTX, Inc. $674.33 03/13/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042336457
Principal investigator 1 ModernaTX, Inc. $674.33 03/13/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042336459
Principal investigator 1 ModernaTX, Inc. $14.58 03/13/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042336461
Principal investigator 1 ModernaTX, Inc. $674.33 03/13/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042336463
Principal investigator 1 ModernaTX, Inc. $674.33 03/13/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042336485
Principal investigator 1 ModernaTX, Inc. $674.33 03/13/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042336487
Principal investigator 1 ModernaTX, Inc. $674.33 03/13/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042336489
Principal investigator 1 ModernaTX, Inc. $674.33 03/13/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042336495
Principal investigator 1 ModernaTX, Inc. $1,002.37 03/13/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042336499
Principal investigator 1 ModernaTX, Inc. $674.33 02/24/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042336071
Principal investigator 1 ModernaTX, Inc. $674.33 02/24/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042336073
Principal investigator 1 ModernaTX, Inc. $674.33 02/24/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042336089
Principal investigator 1 ModernaTX, Inc. $674.33 02/24/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042336091
Principal investigator 1 ModernaTX, Inc. $674.33 02/24/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042336093
Principal investigator 1 ModernaTX, Inc. $674.33 02/24/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042336095
Principal investigator 1 ModernaTX, Inc. $522.45 02/24/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042336111
Principal investigator 1 ModernaTX, Inc. $674.33 02/24/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042336113
Principal investigator 1 ModernaTX, Inc. $674.33 02/24/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042336129
Principal investigator 1 ModernaTX, Inc. $674.33 02/24/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042336131
Principal investigator 1 ModernaTX, Inc. $674.33 02/24/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042336133
Principal investigator 1 ModernaTX, Inc. $674.33 02/24/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042336135
Principal investigator 1 ModernaTX, Inc. $674.33 02/24/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042336167
Principal investigator 1 ModernaTX, Inc. $522.45 02/24/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042336169
Principal investigator 1 ModernaTX, Inc. $674.33 02/24/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042336183
Principal investigator 1 ModernaTX, Inc. $1,002.37 02/24/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042336185
Principal investigator 1 ModernaTX, Inc. $674.33 02/24/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042336187
Principal investigator 1 ModernaTX, Inc. $674.33 02/24/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042336189
Principal investigator 1 ModernaTX, Inc. $674.33 02/24/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042336201
Principal investigator 1 ModernaTX, Inc. $522.45 02/24/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042336203
Principal investigator 1 ModernaTX, Inc. $674.33 02/24/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042336205
Principal investigator 1 ModernaTX, Inc. $674.33 02/24/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042336211
Principal investigator 1 ModernaTX, Inc. $674.33 02/24/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042336213
Principal investigator 1 ModernaTX, Inc. $674.33 02/24/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042336229
Principal investigator 1 ModernaTX, Inc. $674.33 02/24/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042336231
Principal investigator 1 ModernaTX, Inc. $674.33 02/24/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042336233
Principal investigator 1 ModernaTX, Inc. $674.33 02/24/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042336245
Principal investigator 1 ModernaTX, Inc. $674.33 02/24/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042336247
Principal investigator 1 ModernaTX, Inc. $522.45 02/24/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042336249
Principal investigator 1 ModernaTX, Inc. $674.33 02/24/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042336267
Principal investigator 1 ModernaTX, Inc. $674.33 02/24/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042336269
Principal investigator 1 ModernaTX, Inc. $674.33 02/24/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042336279
Principal investigator 1 ModernaTX, Inc. $674.33 02/24/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042336291
Principal investigator 1 ModernaTX, Inc. $522.45 02/24/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042336293
Principal investigator 1 ModernaTX, Inc. $674.33 02/24/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042336295
Principal investigator 1 ModernaTX, Inc. $674.33 02/24/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042336317
Principal investigator 1 ModernaTX, Inc. $674.33 02/24/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042336343
Principal investigator 1 ModernaTX, Inc. $674.33 02/24/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042336351
Principal investigator 1 ModernaTX, Inc. $674.33 02/24/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042336353
Principal investigator 1 ModernaTX, Inc. $674.33 02/24/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042336355
Principal investigator 1 ModernaTX, Inc. $966.28 02/02/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042336153
Principal investigator 1 ModernaTX, Inc. $3,000.00 02/02/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042336191
Principal investigator 1 ModernaTX, Inc. $14.58 01/12/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042335739
Principal investigator 1 ModernaTX, Inc. $14.58 01/12/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042335747
Principal investigator 1 ModernaTX, Inc. $14.58 01/12/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042335749
Principal investigator 1 ModernaTX, Inc. $14.58 01/12/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042335751
Principal investigator 1 ModernaTX, Inc. $765.45 01/12/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042335759
Principal investigator 1 ModernaTX, Inc. $14.58 01/12/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042335761
Principal investigator 1 ModernaTX, Inc. $765.45 01/12/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042335807
Principal investigator 1 ModernaTX, Inc. $14.58 01/12/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042335819
Principal investigator 1 ModernaTX, Inc. $522.45 01/12/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042335821
Principal investigator 1 ModernaTX, Inc. $522.45 01/12/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042335823
Principal investigator 1 ModernaTX, Inc. $522.45 01/12/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042335825
Principal investigator 1 ModernaTX, Inc. $14.58 01/12/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042335831
Principal investigator 1 ModernaTX, Inc. $14.58 01/12/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042335851
Principal investigator 1 ModernaTX, Inc. $14.58 01/12/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042335855
Principal investigator 1 ModernaTX, Inc. $14.58 01/12/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042335863
Principal investigator 1 ModernaTX, Inc. $522.45 01/12/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042335875
Principal investigator 1 ModernaTX, Inc. $765.45 01/12/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042335883
Principal investigator 1 ModernaTX, Inc. $14.58 01/12/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042335885
Principal investigator 1 ModernaTX, Inc. $14.58 01/12/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042335889
Principal investigator 1 ModernaTX, Inc. $522.45 01/12/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042335893
Principal investigator 1 ModernaTX, Inc. $765.45 01/12/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042335905
Principal investigator 1 ModernaTX, Inc. $522.45 01/12/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042335907
Principal investigator 1 ModernaTX, Inc. $3,213.67 01/12/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042335927
Principal investigator 1 ModernaTX, Inc. $14.58 01/12/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042335929
Principal investigator 1 ModernaTX, Inc. $765.45 01/12/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042335941
Principal investigator 1 ModernaTX, Inc. $522.45 01/12/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042335943
Principal investigator 1 ModernaTX, Inc. $14.58 01/12/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042335947
Principal investigator 1 ModernaTX, Inc. $522.45 01/12/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042335957
Principal investigator 1 ModernaTX, Inc. $14.58 01/12/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042335959
Principal investigator 1 ModernaTX, Inc. $522.45 01/12/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042335965
Principal investigator 1 ModernaTX, Inc. $3,213.67 01/12/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042335967
Principal investigator 1 ModernaTX, Inc. $522.45 01/12/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042335971
Principal investigator 1 ModernaTX, Inc. $14.58 01/12/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042335973
Principal investigator 1 ModernaTX, Inc. $14.58 01/12/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042335979
Principal investigator 1 ModernaTX, Inc. $14.58 01/12/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042335981
Principal investigator 1 ModernaTX, Inc. $14.58 01/12/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042335991
Principal investigator 1 ModernaTX, Inc. $522.45 01/12/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042335993
Principal investigator 1 ModernaTX, Inc. $14.58 01/12/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042335995
Principal investigator 1 ModernaTX, Inc. $14.58 01/12/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042336007
Principal investigator 1 ModernaTX, Inc. $14.58 01/12/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042336009
Principal investigator 1 ModernaTX, Inc. $522.45 01/12/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042336025
Principal investigator 1 ModernaTX, Inc. $14.58 01/12/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042336027
Principal investigator 1 ModernaTX, Inc. $522.45 01/12/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042336035
Principal investigator 1 ModernaTX, Inc. $522.45 01/12/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042336037
Principal investigator 1 ModernaTX, Inc. $522.45 01/12/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042336039
Principal investigator 1 ModernaTX, Inc. $522.45 01/12/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042336049
Principal investigator 1 ModernaTX, Inc. $14.58 01/12/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042336059
Principal investigator 1 ModernaTX, Inc. $14.58 01/12/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042336061
Principal investigator 1 ModernaTX, Inc. $14.58 01/12/2023 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042336067